KRAS and cancer: Association of KRAS wild-type cancers (ETV6-NTRK3, TPR-NTRK1, SCLA5-NRG1, and ATP1B1-NRG1 fusions, IDH1 R132C mutation, and mismatch repair deficiency) with early-onset of disease.